JOP20210059A1 - مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم - Google Patents

مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم

Info

Publication number
JOP20210059A1
JOP20210059A1 JOP/2021/0059A JOP20210059A JOP20210059A1 JO P20210059 A1 JOP20210059 A1 JO P20210059A1 JO P20210059 A JOP20210059 A JO P20210059A JO P20210059 A1 JOP20210059 A1 JO P20210059A1
Authority
JO
Jordan
Prior art keywords
antagonists
alpha
treatment
sleep apnea
adrenoceptor subtype
Prior art date
Application number
JOP/2021/0059A
Other languages
English (en)
Inventor
Hahn Michael
Delbeck Martina
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of JOP20210059A1 publication Critical patent/JOP20210059A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي)، على وجه الخصوص مركبات أريل بيبرازين بالصيغة (I) لاستخدامها في طريقة لمعالجة و/أو الوقاية من اضطرابات التنفس المرتبطة بالنوم، ويفضل انقطاع النفس الانسدادي والمركزي أثناء النوم والشخير. الشكل 1
JOP/2021/0059A 2018-09-25 2019-09-19 مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم JOP20210059A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18196686 2018-09-25
PCT/EP2019/075102 WO2020064479A1 (en) 2018-09-25 2019-09-19 α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA

Publications (1)

Publication Number Publication Date
JOP20210059A1 true JOP20210059A1 (ar) 2023-01-30

Family

ID=63685606

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0059A JOP20210059A1 (ar) 2018-09-25 2019-09-19 مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم

Country Status (18)

Country Link
US (1) US20210338662A1 (ar)
EP (1) EP3856183A1 (ar)
JP (1) JP2022502374A (ar)
KR (1) KR20210065948A (ar)
CN (1) CN112714647A (ar)
AU (1) AU2019350264A1 (ar)
BR (1) BR112021003340A2 (ar)
CA (1) CA3113700A1 (ar)
CL (1) CL2021000707A1 (ar)
EA (1) EA202190842A1 (ar)
IL (1) IL281645A (ar)
JO (1) JOP20210059A1 (ar)
MA (1) MA53711A (ar)
MX (1) MX2021003428A (ar)
SG (1) SG11202101821TA (ar)
TW (1) TW202034920A (ar)
UA (1) UA128095C2 (ar)
WO (1) WO2020064479A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220218700A1 (en) * 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
TW202342011A (zh) * 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２－腎上腺素受體亞型Ｃ（α－２Ｃ）拮抗劑與蕈毒鹼受體拮抗劑之組合
WO2023131638A1 (en) * 2022-01-07 2023-07-13 Bayer Aktiengesellschaft 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea
WO2023249924A1 (en) * 2022-06-21 2023-12-28 Apnimed, Inc. (Delaware) Methods of treating sleep apnea with a combination of a cannabinoid and a carbonic anhydrase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7103449A (ar) * 1971-03-15 1972-09-19
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
WO2017031319A1 (en) * 2015-08-18 2017-02-23 Massachusetts Institute Of Technology Noradrenergic drug treatment of obstructive sleep apnea

Also Published As

Publication number Publication date
KR20210065948A (ko) 2021-06-04
JP2022502374A (ja) 2022-01-11
EA202190842A1 (ru) 2021-07-02
MA53711A (fr) 2021-12-29
BR112021003340A2 (pt) 2021-05-11
SG11202101821TA (en) 2021-03-30
IL281645A (en) 2021-05-31
EP3856183A1 (en) 2021-08-04
WO2020064479A1 (en) 2020-04-02
CA3113700A1 (en) 2020-04-02
UA128095C2 (uk) 2024-04-03
CN112714647A (zh) 2021-04-27
US20210338662A1 (en) 2021-11-04
MX2021003428A (es) 2021-06-15
CL2021000707A1 (es) 2021-08-20
AU2019350264A1 (en) 2021-03-25
TW202034920A (zh) 2020-10-01

Similar Documents

Publication Publication Date Title
JOP20210059A1 (ar) مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم
GEP20227366B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
PH12019500131A1 (en) Substituted diazahetero-bicyclic compounds and their use
PH12018501235A1 (en) 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
MX2022010349A (es) Metodos y composiciones para el tratamiento de apnea del sue?o.
PH12019501408A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CR10342A (es) INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3
PH12019501458A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
MX2021009407A (es) Métodos y composiciones para el tratamiento de la apnea del sueño.
PH12021551186A1 (en) Process for producing pharmaceutical dosage forms comprising inhibitors of task-1 and task-3 channels and use thereof for therapy of respiratory disorders
MX2023000369A (es) Combinación de antagonistas del receptor adrenérgico a2 subtipo c (alfa 2c) con un bloqueador de canales task1/3 para el tratamiento de la apnea del sueño.
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
JOP20210113A1 (ar) مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم
EA201991540A1 (ru) Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3 и их применение для лечения нарушений дыхания
EP3976352A4 (en) DENTAL APPLIANCE FOR THE TREATMENT OF BRUXISM AND SLEEP APNEA
EA201991538A1 (ru) Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3, и их применение для лечения нарушений дыхания
EA201990341A1 (ru) Замещенные диазагетеробициклические соединения и их применение
TANG et al. Ulinastatin alleviates patients’ inflammatory response, acute and chronic pain after bilateral total knee arthroplasty
TN2011000037A1 (en) Treatment of pulmonary arterial hypertension